445 related articles for article (PubMed ID: 22371455)
1. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
[TBL] [Abstract][Full Text] [Related]
2. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
3. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
Melaiu O; Stebbing J; Lombardo Y; Bracci E; Uehara N; Bonotti A; Cristaudo A; Foddis R; Mutti L; Barale R; Gemignani F; Giamas G; Landi S
PLoS One; 2014; 9(1):e85935. PubMed ID: 24465798
[TBL] [Abstract][Full Text] [Related]
4. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
[TBL] [Abstract][Full Text] [Related]
7. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
Kachala SS; Bograd AJ; Villena-Vargas J; Suzuki K; Servais EL; Kadota K; Chou J; Sima CS; Vertes E; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
Clin Cancer Res; 2014 Feb; 20(4):1020-8. PubMed ID: 24334761
[TBL] [Abstract][Full Text] [Related]
9. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
Sci Rep; 2013; 3():1870. PubMed ID: 23694968
[TBL] [Abstract][Full Text] [Related]
11. Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.
Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Yokoi K; Osada H; Sekido Y
J Thorac Oncol; 2012 May; 7(5):890-9. PubMed ID: 22722789
[TBL] [Abstract][Full Text] [Related]
12. AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
Sudo H; Tsuji AB; Sugyo A; Abe M; Hino O; Saga T
Int J Oncol; 2014 Feb; 44(2):530-8. PubMed ID: 24253341
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
[TBL] [Abstract][Full Text] [Related]
16. Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.
Kojima M; Kajino K; Momose S; Wali N; Hlaing MT; Han B; Yue L; Abe M; Fujii T; Ikeda K; Hino O
Respir Res; 2020 Jul; 21(1):187. PubMed ID: 32677949
[TBL] [Abstract][Full Text] [Related]
17. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
[TBL] [Abstract][Full Text] [Related]
18. One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.
Hager T; Borchert S; Wessolly M; Mathilakathu A; Mairinger E; Kollmeier J; Mairinger T; Hegedus B; Greimelmaier K; Wohlschlaeger J; Herrmann K; Mairinger FD
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047331
[TBL] [Abstract][Full Text] [Related]
19. The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.
Tucker TA; Dean C; Komissarov AA; Koenig K; Mazar AP; Pendurthi U; Allen T; Idell S
Am J Respir Cell Mol Biol; 2010 Jun; 42(6):685-96. PubMed ID: 19635932
[TBL] [Abstract][Full Text] [Related]
20. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
